ClearB Therapeutics announces upcoming presentations of preclinical hepatitis B data at AASLD 2022 |  Nation/world

ClearB Therapeutics announces upcoming presentations of preclinical hepatitis B data at AASLD 2022 | Nation/world

Concord, Massachusetts – (BUSINESS WIRE) – Oct 24, 2022 –

ClearB Therapeutics, Inc. , a company developing CLB-3000, a therapeutic vaccine designed to provide functional therapy for patients with chronic hepatitis C, said that two abstracts have been accepted for poster presentation at the American Association for the Study of Liver Diseases ( AASLD ) Liver Meeting, to be held in Washington, DC, United States American, 4-8 November 2022.

said Aileen Rubio, Ph.D., CEO of Inc. Chronic hepatitis B (CHB) infection remains an important global disease affecting hundreds of millions of people, with functional treatment still elusive and combination therapies likely to be needed. We believe that re-educating patients’ immune systems to break tolerance to chronic infection with hepatitis B virus through administration of the therapeutic Klerb vaccine could become an important component of combination therapy regimens. “

Abstract No. / Label No.: 36528 / SAT1193

abstract title : Evaluation of Therapeutic Hepatitis B Vaccine CLB-3000 (CLB-405 + CLB-505 with Alhydrogel): A 9 or 15-week toxicological study in New Zealand White Rabbits (NZW) with 4-week convalescence

Date: Friday 4 November 2022

time: 12:00 PM EST

Presenter name: Eileen Rubio, ClearB Therapeutics

Abstract No. / Label No.: 37190 / SAT 1215

abstract title : Immunology after intramuscular vaccination with increasing dose levels of recombinant hepatitis B surface antigen (HBsAg) variants CLB-405 and CLB-505 with or without hydrogel in New Zealand white rabbits (NZW)

Date: Friday 4 November 2022

time: 12:00 PM EST

Presenter name: Eileen Rubio, ClearB Therapeutics

For more information on AASLD 2022, please visit

Liver encounter | AASLD

About ClearB . treatments

ClearB Therapeutics was founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is developing therapeutic vaccines designed to advance the functional treatment of hepatitis B. The work is based on proprietary insights derived from studying the resolution of rare juvenile infections in patients with chronic hepatitis B. For more information, please visit https://clearbtherapeutics.com/.

About Morningside Ventures: Morningside was founded in 1986 by the Chan family, to make private equity and venture capital investments in North America, Europe and Asia Pacific. In the life sciences, Morningside specializes in early stage (pre-clinical through human proof of concept) investments in biopharmaceutical products. They partner with academic founders and entrepreneurs to build world-class companies that want to significantly improve the current state of medicine today and, ultimately, patients’ lives. Morningside’s focus is on investing in excellent biomedical research, where a great deal of knowledge has been gathered and there is a reasonable path forward for clinical development. Their mission is to contribute to a positive, meaningful impact on the prevention or treatment of human disease, and they believe that as long as this is achieved, commercial success will follow.

View source version on businesswire.com:https://www.businesswire.com/news/home/20221024005837/ar/

Contact: Jennifer Locke, Head of Operations and Business

ClearB Therapeutics, Inc.

[email protected]

978,202.4335

Keyword: District of Columbia United States North America

Industry Keyword: Health Infectious Diseases, Other Clinical Trials, Clinical Trials, Pharmacology, Biotechnology

Source: ClearB Therapeutics, Inc.

Copyright Business Wire 2022.

PUB: 10/24/2022 12:50 PM / Disc: 10/24/2022 12:51 PM

http://www.businesswire.com/news/home/20221024005837/en

Copyright Business Wire 2022.


#ClearB #Therapeutics #announces #upcoming #presentations #preclinical #hepatitis #data #AASLD #Nationworld

Leave a Comment

Your email address will not be published. Required fields are marked *